Early Adoption and Prescribing Patterns of Resmetirom: A Multi-Institutional National Analysis - PubMed

7 hours ago

Resmetirom received FDA approval in March 2024 as the first therapy for noncirrhotic MASH with moderate-to-advanced fibrosis.
A retrospective cohort study analyzed 3712 patients across 44 healthcare organizations to assess early prescribing patterns.
The mean age of patients was 57.6 years, 57% were female, and the mean BMI was 33.9 kg/m².
The cohort was predominantly White (73.8%), with Hispanic/Latino (11.7%) and Asian (8.1%) representation.
72% of patients had MASLD diagnoses, 56% had MASH diagnoses, and 15% had cirrhosis codes.
Common comorbidities included dyslipidemia (55%), hypertension (52%), and type 2 diabetes (41%).
GLP-1 receptor agonists like semaglutide, tirzepatide, dulaglutide, and liraglutide were commonly prescribed.
Among 19,643 treatment-eligible patients, only 5.4% received resmetirom.
Treated patients were more frequently Asian or Hispanic and more likely to be prescribed GLP-1 receptor agonists, statins, metformin, or ARBs.
Early prescribing shows preferential use among individuals with higher metabolic burden but reveals potential miscoding or off-label use and significant underutilization.

Hasty Briefsbeta